Selected publications
-
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
BMC Cancer.
2018
Academic Article
GET IT
Times cited: 3 -
NCCN guidelines® insights: Chronic myeloid leukemia, version 1.2017: Featured updates to the NCCN guidelines.
JNCCN Journal of the National Comprehensive Cancer Network.
2016
Article
GET IT
Times cited: 31 -
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
American Journal of Hematology.
2015
Review
GET IT
Times cited: 53 -
Chronic myelogenous leukemia, version 1.2015.
JNCCN Journal of the National Comprehensive Cancer Network.
2014
Academic Article
GET IT
Times cited: 38 -
Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines.
JNCCN Journal of the National Comprehensive Cancer Network.
2013
Review
GET IT
Times cited: 45 -
Ponatinib in patients with refractory acute myeloid leukaemia: Findings from a phase 1 study.
British Journal of Haematology.
2013
Information Resource
GET IT
Times cited: 31 -
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.
Cancer Chemotherapy and Pharmacology.
2013
Academic Article
GET IT
Times cited: 14 -
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
New England Journal of Medicine.
2012
Academic Article
GET IT
Times cited: 461 -
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia.
Cancer Cell.
2012
Academic Article
GET IT
Times cited: 383 -
Sonography of supraspinatus tendon abnormalities in the neutral versus Crass and modified Crass positions: A prospective study.
Journal of Ultrasound in Medicine.
2012
Academic Article
GET IT
Times cited: 3 -
Chronic myelogenous leukemia.
JNCCN Journal of the National Comprehensive Cancer Network.
2012
Review
GET IT
Times cited: 18 -
Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.
Cancer Genetics.
2011
Academic Article
GET IT
Times cited: 16 -
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.
Leukemia Research.
2010
Academic Article
GET IT
Times cited: 6 -
Chronic myelogenous leukemia.
JNCCN Journal of the National Comprehensive Cancer Network.
2009
Review
GET IT
Times cited: 54 -
Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis.
Cancer Cell.
2008
Academic Article
GET IT
Times cited: 183 -
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Journal of Clinical Investigation.
2007
Academic Article
GET IT
Times cited: 287 -
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
New England Journal of Medicine.
2006
Academic Article
GET IT
Times cited: 1317 -
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680.
Cancer Research.
2006
Academic Article
GET IT
Times cited: 226 -
Dynamics of chronic myeloid leukaemia.
Nature.
2005
Academic Article
GET IT
Times cited: 593 -
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.
Proceedings of the National Academy of Sciences of the United States of America.
2005
Academic Article
GET IT
Times cited: 253 -
Detection of BCR-ABL kinase mutations in CD34 + cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Blood.
2005
Academic Article
GET IT
Times cited: 171 -
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Science.
2004
Academic Article
GET IT
Times cited: 1413 -
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Oncogene.
2003
Review
GET IT
Times cited: 181 -
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Proceedings of the National Academy of Sciences of the United States of America.
2002
Academic Article
GET IT
Times cited: 224 -
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Cancer Cell.
2002
Academic Article
GET IT
Times cited: 1328